Rockefeller Capital Management L.P. Inhibikase Therapeutics, Inc. Transaction History

Rockefeller Capital Management L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 14, 2022	SELL	$1.38 - $2.17 $2,070 - $3,255	-1,500 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$2.8 - $6.23 $4,200 - $9,345	1,500 New	1,500 $4,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $33.8M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.